X |
Filing Date |
Trade Date |
Ticker |
Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
D | 2024-03-19 | RNA | Levin Arthur A | Dir | S - Sale+OE | $23.97 | -5,000 | 288,702 | -2% | -$119,848 | |||||
D | 2024-03-13 | RNA | Maclean Michael F | CFO | S - Sale+OE | $24.52 | -40,000 | 44,093 | -48% | -$980,760 | |||||
D | 2024-03-12 | RNA | Levin Arthur A | Dir | S - Sale+OE | $22.03 | -27,641 | 288,702 | -9% | -$609,017 | |||||
DM | 2024-03-08 | RNA | Boyce Sarah | Pres, CEO | S - Sale+OE | $21.70 | -112,000 | 112,117 | -50% | -$2,430,392 | |||||
D | 2024-03-01 | RNA | Boyce Sarah | Pres, CEO | S - Sale+OE | $20.13 | -84,000 | 112,117 | -43% | -$1,691,306 | |||||
2024-01-22 | RNA | Levin Arthur A | Dir | S - Sale | $10.13 | -1,859 | 291,343 | -1% | -$18,832 | ||||||
D | 2024-01-22 | RNA | Boyce Sarah | Pres, CEO | S - Sale+OE | $10.13 | -5,092 | 44,008 | -10% | -$51,582 | |||||
D | 2024-01-22 | RNA | Flanagan W. Michael | CSTO | S - Sale+OE | $10.13 | -4,129 | 35,871 | -10% | -$41,827 | |||||
D | 2024-01-22 | RNA | McCarthy Teresa | CHRO | S - Sale+OE | $10.13 | -2,065 | 17,035 | -11% | -$20,918 | |||||
D | 2024-01-22 | RNA | Maclean Michael F | CFO | S - Sale+OE | $10.13 | -1,616 | 16,884 | -9% | -$16,370 | |||||
D | 2023-03-15 | RNA | Levin Arthur A | Dir | S - Sale+OE | $22.01 | -100 | 293,202 | 0% | -$2,201 | |||||
D | 2023-02-14 | RNA | Levin Arthur A | Chief Scientific Officer | S - Sale+OE | $23.66 | -10,000 | 293,202 | -3% | -$236,567 | |||||
DM | 2023-02-01 | RNA | Boyce Sarah | Pres, CEO | S - Sale+OE | $24.35 | -50,000 | 53,352 | -48% | -$1,217,727 | |||||
D | 2023-01-12 | RNA | Levin Arthur A | Chief Scientific Officer | S - Sale+OE | $22.00 | -10,000 | 275,202 | -4% | -$220,028 | |||||
D | 2022-12-29 | RNA | Levin Arthur A | Chief Scientific Officer | S - Sale+OE | $22.01 | -40,000 | 1,330 | -97% | -$880,568 | |||||
DM | 2022-08-12 | RNA | Levin Arthur A | Chief Scientific Officer | S - Sale+OE | $22.10 | -80,000 | 275,202 | -23% | -$1,767,666 | |||||
DM | 2022-08-24 | RNA | Boyce Sarah | Pres, CEO | S - Sale+OE | $22.88 | -49,900 | 0 | -100% | -$1,141,614 | |||||
D | 2022-08-15 | RNA | Boyce Sarah | Pres, CEO | S - Sale+OE | $22.47 | -100 | 0 | -100% | -$2,247 |
A | Amended filing |
D | Derivative transaction in filing (usually option exercise) |
E | Error detected in filing |
M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
S - Sale | Sale of securities on an exchange or to another person |
S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
P - Purchase | Purchase of securities on an exchange or from another person |